Arecor

Executive Summary

Arecor is a UK-based clinical-stage biopharmaceutical company focused on developing enhanced formulations of existing therapeutic proteins, particularly insulins and peptides for diabetes and cardiometabolic diseases. Leveraging its proprietary Arestat® technology platform, the company aims to improve the stability, delivery, and performance of these drugs, potentially leading to better patient outcomes and competitive advantages over standard therapies. Arecor's strategy combines a proprietary pipeline with partnerships with pharmaceutical and medtech companies, allowing for both internal value creation and external validation. The company is currently in Phase 1 clinical development, with a focus on advancing its lead candidates through proof-of-concept studies. Given the high unmet need in diabetes care and the potential of its formulation technology to differentiate existing therapies, Arecor represents an interesting opportunity in the drug delivery space. However, as a private company with limited public disclosures, significant risks remain regarding clinical execution, financing, and regulatory pathways.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead insulin formulation70% success
• Q4 2026New partnership or licensing deal with a major pharma40% success
• H1 2027Series C funding round to advance pipeline60% success